// App-Quantinova.ai

AB0556 (2021) : COMPARING EFFICACY OF GUSELKUMAB VERSUS USTEKINUMAB IN PATIENTS WITH PSORIASIS ARTHRITIS: AN ADJUSTED COMPARISON USING INDIVIDUAL PATIENT DATA FROM DISCOVER 1&2 AND PSUMMIT TRIALS

Researchers

Presenter

  • J. Diels

Principal Investigators

  • A. Schubert

  • F. Hassan

  • S. Peterson

  • W. Noel

Medical Centers

  • Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium

  • JanssenCilag Ltd, HEMAR Department, Beerse, Belgium

  • Janssen-Cilag Poland, HEMAR Department, Warsaw, Poland

  • Janssen-Cilag Ltd, HEMAR Department, High Wycombe, United Kingdom

  • Janssen Global Services, LLC, Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, United States of America

Locations

  • Belgium

  • Poland

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Tumor necrosis factor

  • Albumin/creatinine

Drug/Treatment

  • Ustekinumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved